Tratamiento de la necrólisis epidérmica tóxica

Medicina Clinica

Volumn 111, Issue 1, 1998, Pages 27-31

  Arévalo, José M ^a,b   Lorente, José A ^b  

^a Unidad de Grandes Quemados   (Spain)

^b HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; BIOMATERIAL; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT;

CLINICAL FEATURE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; PATHOGENESIS; REVIEW; SEPSIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT PLANNING;

EPIDERMAL NECROLYSIS, TOXIC; HUMANS;

EID: 0032513794     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Avakian R, Flowers FP, Araujo OE, Ramos Careo FA. Toxic epidermal necrolysis: a review. J Am Acad Dermatol 1991; 25: 69-79.
2. Zoltie N, Verlende P, O'Neill, McKenzie AW. Lyell's syndrome on a burns unit. Burns 1994; 204: 368-370.
3. Timsit JF, Mion G, Gulluche YL. Severe hypothermia occurring during the course of toxic epidermal necrolysis in patients treated with air fluidized beds. Arch Dermatol 1991; 127: 739-743.
4. Halebian PH, Shires G, Burn unit treatment of severe exfoliative disorders. Annu Rev Med 1989; 40: 147-153.
5. Halebian PH, Corder V, Finkelsten JL, Madden MR, Shires G. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503-511.
6. Revuz J, Penso D, Rojeau JC. Toxic epidermal necrolysis. Arch Dermatol 1987; 123: 1.160-1.165.
7. Lyell A. Toxic epidermal necrolysis: an eruption resumbling scalding of the skin. Br J Dermatol 1956; 68: 355-361.
8. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Rojeau JC. Clinical classification of cases of toxic epidermal necrolysis. Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993; 129: 92-96.
9. Patterson R, Dykewicz MS, Gonzales A et al. Erythema multiforme and Stevens-Johnson syndrome: descriptive and therapeutic controversy. Chest 1990; 98: 331-336.
10. Wilkins J, Morrison L, White CR. Occulocutaneous manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Dermatol Clin 1992; 10: 571-582.
11. Rojeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1.600-1.607.
12. Rojeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal recrolysis Lyell syndrome: incidence and drug etiology in France. 1981-1985. Arch Dermatol 1990; 126: 37-42.
13. Schöpf E, Stühmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol 1991; 127: 839-842.
14. Chan HL, Stern RS, Ardnt KA et al The incidence of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126: 43-47.
15. Naldi L, Locafi F, Marchesi L, Cainelli T. Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol 1990; 126: 1.103-1.104.
16. Prendiville JS, Hebert AA. Greenwald MJ, Esterly NB. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1987; 115: 881-887.
17. Kim PS, Goldfarb IW, Gaisford JC, Slater H. Stevens-Johnson syndrome and toxic epidermal necrolysis: a pathophysiologic review with recommendations for a treatment protocol. J Burn Care Rehabil 1983; 4: 91-100.
18. Fortuny C, Palomeque A, Pastor X, Canos J, Jimenez R. Necrólisis epidérmica toxica Forma grave con importante afectacion pluriorgänica. An Esp Pediatr 1991; 35: 59-61.
19. Muǹoz F, Mallent J, Laredo C, Domënech E, Tafalla M. Tafalla M. Necroisis epidérmica tóxica: presentación de dos casos pediátricos. An Esp Pediatr 1996; 45: 71-75.
20. Kelemen III JJ, Cioffi WC, McManus WF, Mason AD, Pruitt BA. Burn ce:er care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995; 180: 273-278.
21. Kucan JO Use of Biobrane in the treatment of toxic epidermal necrolysis. J Burn Care Rehabil 1995; 16: 324-328.
22. Revuz J, Penson D, Roujeau JC et al. Toxic epidermal necrolysis: clinical findings and prognostic factors in 87 patients. Arch Dermatol 1987: 123: 1.160-1.166.
23. Rojeau JC, Stern RS. Severe cuteneous adverse reactions to drugs. N Engl J Med 1994; 331: 1.272-1.285.
24. Stern RS, Chan HL. Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis. J Am Acad Dermatol 1989; 21: 317-322.
25. Correia O, Chosidow O, Saiag P, Bastuji-Garin S, Revuz J, Rojeau JC. Evolving pattern of drug induced toxic epidermal necrolysis. Dermatology 1993: 186: 32-37.
26. Heimbach DM, Engrav LH, Marvin JA et al. Toxic epidermal necrolysis: a step forward in treatment. JAMA 1987; 257: 2.171-2.175.
27. Navarro A, Elizalde J, Boto A, Pujol E. Necrólisis epidérmica tóxica en una paciente en tratamiento con allas dosis de deflazacort. Med Clin (Barc) 1996; 106: 599.
28. Halebian PH, Madden MR, Finkestein JL et a . Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Snrg 1986; 204: 503-511.
29. Halebian P, Corder V, Herndon D. A burn centre experience with toxic epidermal necrolysis. J Burn Care Rehabil 1983. 4: 176-183.
30. Saiag P. Caumes E. Chosidow O et al. Drug-induced toxic epidermal necrolysis (Lyeli syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992; 26: 567-574.
31. Goldstein SM, Wintroub BW, Elias PM, Wuepper KD. Toxic epidermal necrolysis: unniuddying the waters. Arch Dermatol 1987; 123: 1.153-1.155.
32. Lyell A. Toxic epidermal necroysis the scalded skin syndrome: a reappraisal. Br J Dermatol 1979; 100: 69-86.
33. Guillaume JC, Roujeau JC, Revuz J et al. The culprit drugs in 87 cases of toxic epidermal necrolysis Lyell syndrome. Arch Dermatol 1987; 123: 1.166-1.170
34. Yotin J, Biancaini JR, Owens JA. Etiological factors in Stevens-Johnson syndrome. South Med J 1980; 73: 599-602
35. Howland WW, Golitz LE, Weston WL, Huff JC Erythema multiforme: clinical histopathologic and immunologic study. J Am Acad Dermatol 1984; 10: 438-446.
36. Rojeau JC. Revuz J. Toxic epidermal necrolysis: an expanding fiel of knowledge. J Am Acad Dermatol 1994; 31: 301-302.
37. Merot Y, Gravallese E, Guillen FJ, Murphy GF. Lymphocyte subsets and langerhans' cells in toxic epidermal necrolysis. Arch Dermatol 1986; 122: 455-458
38. Villada G, Roujeau JC, Clerici T et al. Immunopathology of toxic epidermal necrolysis Keratinocytes. HLA-DR expression. Langerhans cells and mononuclear cells: an immunopathologic study of five cases. Arch Dermatol 1992; 128: 50-53.
39. Miyauchi H, Hosokawa M, Akaeda T et al. T-cell subsets in drug induced toxic epidermal necrolysis. Arch Dermatol 1991; 127: 851-855.
40. Heng MC, Allen SG. Efficiency of cyclophosphamides in toxic epidermal necrolysis: clinical and pathophysiologic aspects. J Am Acad Dermatol 1991; 25: 778-786
41. Parson JM. Toxic epidermal necrolysis. Int J Dermatol 1992; 31: 749-768.
42. Marvin JA, Heimbach DM, Engrav LH, Harner TJ. Improved treatment of Stevens-Johnson syndrome. Arch Surg 1984; 119: 601-605.
43. Grenn D, Law E, Still M. An approach to the management of toxic epidermal necrolysis in a burn centre. Burns 1993; 195: 411-413.
44. Parrilla P, Rodriguez JM, Soria V. Rotura esofágica como complicación del sindrome de Lyell. Med Clin (Barc) 1996; 106: 719.
45. Yarbrough DR. Experience with toxic epidermal necrolysis treated in a burn center. J Burn Care Rehabil 1996; 17: 30-33.
46. Roujeau JC, Chosidow O, Saiag P. Guillaume JC. Toxic epidermal necrolysis Lyell syndrome. J Am Acad Dermatol 1990; 23: 1.039-1.058.
47. Resnick SD. Staphylococcal toxin mediated syndromes n childhood. Semin Dermatol 1992; 11: 11-18.
48. Canosc JJ. Barza M. Soft tissue infections. Rheum Dis Clin North Am 1993; 15: 235-239
49. Finlay AY, Richards J, Holt PJA. Intensive therapy unit management of toxic epidermal necrolysis: practical aspects. Clin Exp Dermatol 1982; 7: 55-60.
50. Management of toxic epidermal necrolysis [editorial]. Lancet 1984; 2: 1.250-1.252.
51. Revuz J. Rojeau JC, Guillaume JC. Treatment of toxic epidermal necrolysis. Creteil's experience. Arch Dermatol 1987; 123: 1.156-1.158.
52. Bjornberg A, Bjornberg K, Gisslen H. Toxic epidermal necrolysis with opthalmic complications. Acta Ophthalmol 1964; 42: 1.084-1.095
53. Howard GM. The Stevens-Johnsons syndrome, oculat prognosis and treatment. Am J Ophthalmol 1963; 55: 893-900
54. Rojeau JC, Koso M, Andre C. Sjögren-like syndrome after drug induced toxic epidermal necrolysis. Lancet 1985; 2: 609-611
55. Halebian PH, Shires GT. Burn unit treatment of acute. severe exfoliating disorders. Annu Rev Med 1989; 40: 137-147.
56. Herndon DN. Toxic epidermal necrolysis: a systemic and dermatologic disorder best trested with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J Am Coll Surg 1995; 180: 340-342
57. Paller AS, Nelson A, Steffen L, Bottschalk Z, Kaizer H. T-lymphocyte subset in the lesional skin of allogenic and autologous bone marrow transplant patients. Arch Dermatol 1988; 124: 1.795-1.801
58. Ginsburg CM. Stevens-Johnson syndrome in children. Pediatr Infect Dis 1982; 1: 155-158
59. Knoo AKM, Foo CL. Toxic epidermal necrolysis in a burns centre: a 6 years review. Burns 1996; 20: 275-278.
60. Serfling S, Sudden onset of blisters and ulcerations in a healthy man. Arch Dermatol 1993; 129: 776-777.
61. Taylor JA, Grube B, Heimbach DM. Toxic epidermal necrolysis, a comprehensive approach multidisciplinary management in a burn ceter. Clin Pediatr 1989; 28: 404-407.
62. Renfro L, Grant JM, Daman LA. Drug induced toxic epidermal necrolysis treated with ciclosporine. Int J Dermatol 1989; 28: 441-443
63. Madalene C, Sunni G. Efficacy of cyclophosphamide in toxic epidermal necrolysis. J Am Acad Dermatol 1991; 25: 778-786.
64. Razzaque AA, Hombal GM. Cyclophosphamide Cytosan. J Am Acad Dermatol 1984; 11 (Supl): 111-112.
65. Hertl M, Bohlen H, Merk HF. Efficacy of cyclophosphamide in toxic epidermal necrolysis. J Am Acad Dermatol 1993; 129: 92-96
66. Izumi AK, Griffith RF, Heaton CL. Topical silve nitrate in loxic epidermal necrolysis. Cutis 1970; 6: 865-868
67. Roher TE. Ahmed R. Toxic epidermal necrolysis. Int J Dermatol 1991; 30: 457-466.
68. Rodeheaver GT, Harstell MS, Brent C et al nfluence of Biobrane construction on adherence. J Burn Care Rehabil 1995; 16: 321-323.
69. Smith DJ. Use of Biobrane in wound management. J Burn Care Rehabil 1995; 16: 317-320.
70. Sowder LL. Biobrane wound dressing used in the treatment of toxic epidermal necrolysis: a case report. J Burn Care Rehabil 1990; 11: 237-239.
71. B shop JF, Demling RH, Hansbrough JF et al. Indications for use of Biobrane in wound management. Proceedings of a conference held in Houston, Texas. [Sumario]. J Burn Care Rehabil 1995; 16: 341-342.
72. Prasad JK, Feller I, Thompson PD. Use of amnion for the treatment of Stevens-Johnson syndrome. J Trauma 1986; 26: 945-946